US Epilepsy Foundation’s Shark Tank Investment Prize 2025

Neumirna Therapeutics has won the US Epilepsy Foundation’s ‘Shark Tank’ Investment Prize 2025, securing $200,000.

The prize, awarded by the US-based NeuroImpact Fund, followed a live pitch at the Epilepsy Therapies & Diagnostics Development (ETDD) Symposium in Leesburg, Virginia – an event modelled after the U.S. Shark Tank format.

CEO Dr Janine Erler presented Neumirna’s RNA-based approach to drug-resistant epilepsy to an international panel of clinical experts, industry leaders and investors.

Neumirna’s win recognises their paradigm-shifting work – moving from symptomatic management towards a truly disease-modifying treatment. The investment will fund essential safety work, enabling the inclusion of people of childbearing potential in upcoming studies.

It’s a key milestone to building a treatment that is safe, effective, and accessible for all people with drug-resistant epilepsy.

Key points

• The USD 200,000 will allow inclusion of people of childbearing potential.
• Neumirna is developing the drug candidate NMT.00, targeting microRNA-134 (miR-134).
• NMT.001 has shown promising effects in an NIH-validated preclinical model.